Bispecific Trial in Myeloma Sparks Talks of 'Functional Cure'

(MedPage Today) -- ORLANDO--Combining teclistamab (Tecvayli) with subcutaneous daratumumab-hyaluronidase (Darzalex Faspro) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory...